Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) stands out as a compelling pick for investors following Louis Navellier’s growth-focused strategy. The company meets multiple criteria outlined in The Little Book That Makes You Rich, demonstrating strong earnings momentum, revenue growth, and profitability. Below, we examine why AUPH fits this approach.

Key Strengths Aligning with Navellier’s Growth Criteria

• Earnings Revisions & Surprises: Analysts have raised next-quarter EPS estimates by 35.2% over the past three months. AUPH has also delivered four consecutive positive earnings surprises, averaging a 197.4% beat.
• Revenue Growth: Year-over-year revenue growth stands at 29.2%, while quarterly sales increased 24.2%, reflecting sustained demand for its lupus nephritis drug, LUPKYNIS.
• Expanding Profitability: Operating margins surged 154.5% over the past year, indicating improved cost efficiency.
• Strong Cash Flow: Free cash flow grew 198.2%, reinforcing financial flexibility.
• Earnings Momentum: Quarterly EPS growth accelerated to 633.3%, far exceeding the 83.3% growth from the same quarter a year ago.
• High Return on Equity: An 11.4% ROE suggests effective use of shareholder capital.

Fundamental Snapshot

Aurinia’s financial health is solid, with a strong balance sheet (Altman-Z score of 3.51) and manageable debt. While its P/E ratio of 30.25 appears high, it remains cheaper than 94% of biotech peers. Analysts expect 71.7% annual EPS growth, supporting its valuation.

For a deeper dive, review the full fundamental analysis report.

Our Little Book Growth Screener lists more stocks matching these criteria.

Disclaimer

This is not investing advice. Conduct your own research before making investment decisions.